These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19586077)

  • 1. The cost of dementia in Europe: a review of the evidence, and methodological considerations.
    Jönsson L; Wimo A
    Pharmacoeconomics; 2009; 27(5):391-403. PubMed ID: 19586077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.
    Gustavsson A; Jonsson L; Rapp T; Reynish E; Ousset PJ; Andrieu S; Cantet C; Winblad B; Vellas B; Wimo A;
    J Nutr Health Aging; 2010 Oct; 14(8):648-54. PubMed ID: 20922341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America.
    Takizawa C; Thompson PL; van Walsem A; Faure C; Maier WC
    J Alzheimers Dis; 2015; 43(4):1271-84. PubMed ID: 25159675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
    Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
    Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Costs of Dementia in Europe: An Updated Review and Meta-analysis.
    Jönsson L; Tate A; Frisell O; Wimo A
    Pharmacoeconomics; 2023 Jan; 41(1):59-75. PubMed ID: 36376775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
    Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
    Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
    Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina.
    Allegri RF; Butman J; Arizaga RL; Machnicki G; Serrano C; Taragano FE; Sarasola D; Lon L
    Int Psychogeriatr; 2007 Aug; 19(4):705-18. PubMed ID: 16870037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of Care of Agitation Associated With Dementia in 8 European Countries: Results From the RightTimePlaceCare Study.
    Costa N; Wübker A; De Mauléon A; Zwakhalen SMG; Challis D; Leino-Kilpi H; Hallberg IR; Stephan A; Zabalegui A; Saks K; Molinier L; Wimo A; Vellas B; Sauerland D; Binot I; Soto ME;
    J Am Med Dir Assoc; 2018 Jan; 19(1):95.e1-95.e10. PubMed ID: 29275939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
    Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
    Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project.
    Wimo A; Jönsson L; Gustavsson A; McDaid D; Ersek K; Georges J; Gulácsi L; Karpati K; Kenigsberg P; Valtonen H
    Int J Geriatr Psychiatry; 2011 Aug; 26(8):825-32. PubMed ID: 21744385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.
    Reed C; Happich M; Argimon JM; Haro JM; Wimo A; Bruno G; Dodel R; Jones RW; Vellas B; Belger M
    J Alzheimers Dis; 2017; 57(3):797-812. PubMed ID: 28304285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
    Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
    J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.